Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Future Oncology (London, England)|March 1, 2019
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myelomaCaitlin Costello, Faith E Davies, Gordon Cook, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 21, 2023
Heart-liver-kidney transplantation for AL amyloidosis using normothermic recovery and storage from a donor following circulatory death: Short-term outcome in a first-in-world experienceAleah L Brubaker, Marcus A Urey, Raeda Taj, et al.
Blood Cancer Journal|October 6, 2025
Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analysesLaahn Foster, Larry D Anderson, Alfred Chung, et al.
Blood|September 27, 2024
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA studyAshraf Badros, Laahn Foster, Larry D Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2019
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice GuidelineJoseph Mikhael, Nofisat Ismaila, Matthew C Cheung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2026
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living GuidelineLisa K Hicks, Hans J Messersmith, Samer Al Hadidi, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 23, 2019
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progressionSourav Banerjee, Tiantian Wei, Jue Wang, et al.
Blood Advances|February 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Annals of Hematology|May 10, 2021
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the USFaith Davies, Robert Rifkin, Caitlin Costello, et al.
Blood|June 2, 2020
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantationMatthew S Davids, Haesook T Kim, Caitlin Costello, et al.
Pageof 7